Thioacetamide (TAA) is an indirect hepatotoxin commonly used to induce experimental liver injury. It is metabolized by CYP2E1 into reactive metabolites that covalently bind to proteins and lipids, leading to oxidative stress and centrilobular necrosis, hepatocyte death, and M1/M2 macrophage-dominated inflammation. TAA is widely used to establish models of chronic liver fibrosis, hepatic encephalopathy, and liver cancer.